Espicom


The Pharmaceutical Market: Japan

Published 09 February 2015

  • 157 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
The Pharmaceutical Market: Japan

Table of Contents

BMI Industry View
7
SWOT
8
Political
10
Economic
11
Industry Forecast
12
Pharmaceutical Market Forecast
12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Japan 2010-2018)
14
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2010-2018)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2010-2018)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2010-2018)
16
Prescription Drug Market Forecast
17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Japan 2010-2018)
18
Patented Drug Market Forecast
18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Japan 2010-2018)
20
Generic Drug Market Forecast
20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Japan 2010-2018)
24
Over The Counter Medicine Market
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Japan 2010-2018)
28
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Japan 2012-2018)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (Japan 2012-2018)
30
Other Healthcare Data
30
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
33
Economic Analysis
33
Table: Economic Activity (Japan 2009-2018)
35
Industry Risk Reward Index
36
Asia Pacific Risk/Reward Index
36
Japan Risk/Reward Index
42
Rewards
42
Risks
43
Market Overview
44
Industry Trends And Developments
46
Epidemiology
46
Healthcare Sector
49
Clinical Trials
50
Regulatory Development
53
Regulatory Regime
53
Table: OTC Drug Categories In Japan
56
Table: Prescription-To-OTC Switches In Japan (2000-2012)
56
Table: NCEs Approved by Origin, 2000-2010
61
Table: Timeline Of NHI Drug List Price Cuts In Japan, 1992-2010
61
Competitive Landscape
64
Pharmaceutical Sector
64
Table: Top 15 Pharmaceutical Companies According To Market Capitalisation On The Tokyo Stock Exchange
65
Foreign Generic Industry
66
Pharmaceutical Wholesale
67
Pharmaceutical Retail
68
Company Profile
82
Takeda Pharmaceutical Company
82
Astellas
90
Eisai
98
Daiichi Sankyo
105
Mitsubishi Tanabe
112
Sawai Pharmaceutical
115
Pfizer
118
Sanofi
122
Merck & Co
126
Novartis
130
GlaxoSmithKline
135
AstraZeneca
139
Demographic Forecast
143
Table: Population Headline Indicators (Japan 1990-2025)
144
Table: Key Population Ratios (Japan 1990-2025)
144
Table: Urban/Rural Population & Life Expectancy (Japan 1990-2025)
146
Table: Population By Age Group (Japan 1990-2025)
146
Table: Population By Age Group % (Japan 1990-2025)
147
Glossary
148
Methodology
150
Pharmaceutical Expenditure Forecast Model
150
Healthcare Expenditure Forecast Model
150
Notes On Methodology
151
Risk/Reward Index Methodology
152
Index Overview
153
Table: Pharmaceutical Risk/Reward Index Indicators
153
Indicator Weightings
154
OVERVIEW OF THE PHARMACEUTICAL MARKET IN JAPAN

Japan's ageing and affluent population represents strong opportunities for foreign drugmakers. However, given its weak macroeconomic, there is a risk that the country will not be able to sustain its generous welfare for the people and will seek to save costs through the use of more generic drugs and price cuts. Nevertheless, the current profile broods well for generic drugmakers as well as companies focusing on eldercare and chronic disease management.

Headline Expenditure Projections

Pharmaceuticals: JPY10,157bn (US$127.4bn) in 2011 to JPY10,206bn (US$130.9bn) in 2012; +0.5% in local currency terms and +2.7% in US dollar terms. Ourforecast is unchangedsinceQ312.

Healthcare: JPY47,810bn (US$599.60bn) in 2011 to JPY49,305bn (US$632bn) in 2012; +3.0% in local currency terms and +5.4% in US dollar terms. Ourforecasthasbeenrevisedupwardsslightly from Q412 following reassessment of historic data.

Medical Devices: JPY2,220bn (US$27.8bn) in 2011 to JPY2,212bn (US$28.4n) in 2012; -0.5% in local currency terms and +1.9% in US dollar terms. Forecast slightly downgradedfrom Q412due to reassessment of historic values.

Risk/RewardRating

In Q113, Japan's score on BMI's Asia PacificPharmaceutical Risk/Reward Ratings maintains at 77.0 and continues to enjoy its status as the most attractive pharmaceutical market in the region. The country scores highly for all indicators in the proprietary model, including an ageing population, large pharmaceutical market, lack of corruption and extensive bureaucracy and will continue to be targeted by multinational drugmakers both innovative and generics.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%